Amplification of HER2 and TOP2A and Deletion of TOP2A Genes in Breast Cancer Investigated by New FISH Probes

Acta Oncologica

Volumn 43, Issue 1, 2004, Pages 35-42

  Olsen, Karen E ^a   Knudsen, Helle ^b   Rasmussen, Birgitte B ^c   Balslev, Eva ^d   Knoop, Ann ^a   Ejlertsen, Bent ^e   Nielsen, Kirsten V ^f   Schönau, Andreas ^f   Overgaard, Jens ^g  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c ROSKILDE HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e Rigshospitalet   (Denmark)

^f AGILENT TECHNOLOGIES   (United States)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; TOPOISOMERASE 2 ALPHA GENE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ERROR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCREENING;

ADULT; AGED; BIOPSY, NEEDLE; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 1442265950     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310019007     Document Type: Article

References (27)

1. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002; 29: 231-45.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
3. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991; 6: 137-43.
4. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112: S53-67.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
6. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
7. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8: 1061-7.
8. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-16.
9. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999; 26: 142-50.
10. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156: 839-47.
11. Lebeau A, Deimling D, Kaltz C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001; 19: 354-63.
12. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771-7.
13. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 2002; 126: 803-8.
14. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 63-72.
15. Masood S, Bui MM, Yung JF, et al. Reproducibility of LSI HER-2/neu SpectrumOrange and CEP 17 SpectrumGreen Dual Color deoxyribonucleic acid probe kit. For enumeration of gene amplification in paraffin-embedded specimens: a multicenter clinical validation study. Ann Clin Lab Sci 1998; 28: 215-23.
16. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19: 2714-21.
17. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000; 13: 37-45.
18. Farabegoli F, Ceccarelli C, Santini D, et al. c-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples. Int J Cancer 1999; 84: 273-7.
19. Offersen BV, Sørensen FB, Yilmaz M, Knoop A, Overgaard J. Chalkley estimates of angiogenesis in early breast cancer. Relevance to prognosis. Acta Oncol 2002; 41: 695-703.
20. Taneja KL, Chavez EA, Coull J, Lansdorp PM. Multicolor fluorescence in situ hybridization with peptide nucleic acid probes for enumeration of specific chromosomes in human cells. Genes Chromosomes Cancer 2001; 30: 57-63.
21. Nielsen K, Hyldig-Nielsen J, Williams B. US patent application WO 03/027328A2; 2003.
22. Larsimont D, Di Leo A, Rouas G, et al. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. Anticancer Res 2002; 22: 2485-90.
23. Ellis IO, Dowsett M, Bartlett J, et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000; 53: 890-2.
24. Tsuda H, Akiyama F, Terasaki H, et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 2001; 92: 2965-74.
25. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 1997; 10: 720-7.
26. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001; 61: 5345-8.
27. Tsuda HH. Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human breast cancer. Breast Cancer 2001; 8: 38-44.